
News|Articles|December 11, 2014
The Need to Study Tissue Biomarkers
Author(s)David L. Rimm MD, PhD
David L. Rimm MD, PhD, from Yale School of Medicine, discusses the need for further research into tissue biomarkers in breast cancer.
Advertisement
Clinical Pearls
David L. Rimm MD, PhD, Professor of Pathology and of Medicine (Medical Oncology), Director of Pathology Tissue Services, Director of Translational Pathology, Yale School of Medicine, discusses the need for further research into tissue biomarkers in breast cancer.
- Tissue biomarkers may help to determine which patients will respond to certain drugs.
- Biologically, cancers are different. It is important to be able to determine how patients will respond to treatment.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5










































